Phosphatidylinositol increases HDL-C levels in humans

• Published in: Journal of lipid research Vol. 46; no. 2; pp. 350 - 355
• Main Authors: Burgess, Jim W., Neville, Tracey A-M., Rouillard, Patricia, Harder, Zdena, Beanlands, Donald S., Sparks, Daniel L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2005; Elsevier
• Subjects: Adult; Apolipoprotein A-I - metabolism; Bile - metabolism; cholesterol; Cholesterol - metabolism; Cholesterol, HDL - blood; Cohort Studies; Fasting; Female; HDL elevating agents; high density lipoprotein-cholesterol; Humans; Liver - metabolism; Male; Niacin - pharmacology; Phosphatidylinositols - pharmacology; Time Factors; triglycerides; Triglycerides - blood; Triglycerides - metabolism; cholesterol; HDL elevating agents; triglycerides; high density lipoprotein-cholesterol
• ISSN: 0022-2275; 1539-7262
• DOI: 10.1194/jlr.M400438-JLR200

Studies have shown that phosphatidylinositol (PI) can stimulate reverse cholesterol transport by enhancing the flux of cholesterol into HDL and by promoting the transport of high density lipoprotein-cholesterol (HDL-C) to the liver and bile. The goal of this study was to determine the safety and therapeutic value of PI after oral administration to normolipidemic human subjects. We performed a randomized 2 week study in 16 normolipidemic subjects. Subjects received either 2.8 or 5.6 g of PI, with or without food. PI was well tolerated by all subjects. PI significantly affected the levels of HDL-C and triglyceride in the plasma of subjects receiving PI with food. The lower dose showed a 13% increase in HDL-C, whereas the high dose showed an increase of 18% over the 2 week period. Both low- and high-dose groups showed significant increases in plasma apolipoprotein A-I. The high dose of PI also decreased plasma triglycerides by 36% in the fed subjects. These data suggest that after only 2 weeks, PI may have a comparable therapeutic value to niacin, with negligible side effects.